Dr Thomas Marjot is a Principal Investigator at the Roger Williams Institute of Liver Studies, King’s College London and Honorary Consultant Hepatologist at King’s College Hospital. His research programme focuses on experimental and translational hepatology, with a particular emphasis on steatotic liver disease, including MASLD, MetALD, and alcohol-related liver disease.

He leads the Liver Metabolism and Biological Rhythms (LIMBR) Group, which investigates how circadian biology regulates liver metabolism in humans and how disruption of biological timing contributes to metabolic dysfunction. His work centres on mechanistic, early-phase experimental medicine studies, integrating advanced metabolic phenotyping, stable isotope methodologies, multi-omics approaches, and interventional human models. A central aim of his research is to translate mechanistic insights into therapeutic strategies. This includes developing and testing novel interventions targeting metabolic and circadian pathways, with applications in metabolic liver disease and in populations exposed to circadian disruption, such as shift workers. He completed a Wellcome Trust-funded DPhil at the University of Oxford in 2023, focusing on circadian regulation liver metabolism, and has led a range of translational human studies spanning metabolism and circadian biology.

Experimental Medicine Platform

We leverage access to a broad spectrum of patients with steatotic liver disease through specialist clinical services and established biobanks to enable recruitment into deeply phenotyped human studies. Our experimental medicine platform integrates intensive metabolic, imaging, and immunological profiling, including hyperinsulinaemic–euglycaemic clamp studies, stable isotope methodologies, liver and brain MRI, multi-tissue sampling, and advanced immune characterisation. We perform muscle and adipose tissue biopsies to investigate the systemic nature of metabolic liver disease, supported by multi-omics and proteomic analyses.

These approaches are combined with controlled mechanistic interventions, including novel therapeutic agents, circadian and behavioural challenges, and time-of-day experimental paradigms. This enables direct testing and validation of mechanistic hypotheses in humans, providing a translational bridge from preclinical discovery to early-phase clinical application.

• Google Scholar: https://scholar.google.com/citations?user=s4mfRs4AAAAJ&hl=en
• LinkedIn: https://www.linkedin.com/in/thomas-marjot/
• Twitter / X: @tom_marjot